Skip to main content
Whitehawk Therapeutics, Inc. logo

Whitehawk Therapeutics, Inc. — Investor Relations & Filings

Ticker · WHWK ISIN · US00032Q1040 LEI · 549300G3U7TKW1M58L09 US Professional, scientific and technical activities
Open in API
Filings indexed 516 across all filing types
Latest filing 2018-04-06 Regulatory Filings
Country US United States of America
Listing US WHWK

About Whitehawk Therapeutics, Inc.

https://ir.whitehawktx.com/

Whitehawk Therapeutics, Inc. is a preclinical-stage oncology company focused on developing advanced antibody-drug conjugate (ADC) therapies. The company applies next-wave platform technologies to established tumor biology to create treatments for difficult-to-treat cancers. Its portfolio features three ADC assets, which are engineered to overcome the limitations of first-generation predecessors through improved tumor targeting and clinical strategies. These assets are in-licensed from WuXi Biologics under an exclusive agreement for global development and commercialization.

Recent filings

Filing Released Lang Actions
S-8 Filing
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock option plans. It includes details about the securities to be registered, the registration fee, and signatures of company officers and directors. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length and content confirm it is not a brief announcement or a report publication notice but a full registration statement filing.
2018-04-06 English
10-K/A Filing
Annual Report FY 2017
2018-04-06 English
S-3/A Filing
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used for registering securities for sale to the public. It includes a base prospectus for offering up to $150 million of various securities including common stock, preferred stock, debt securities, warrants, and units. The document is not a financial report, earnings release, or management discussion, but rather a regulatory filing related to capital raising activities. It is not an announcement of a report but the actual registration statement document. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the full filing, not just an announcement or notice.
2018-04-06 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement, specifically a lease amendment. It does not contain financial statements or detailed financial data, nor is it an earnings release or annual/interim report. It is not a report publication announcement since it contains substantive information about the lease amendment. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into more specific categories like capital update or management changes.
2018-04-02 English
4 Filing
Director's Dealing
2018-03-23 English
4 Filing
Director's Dealing
2018-03-21 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.